Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PLEC | Q15149 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787955 | 0.84 | ALDH1A1 (0.54) | LMNATSHRSMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL3789681 | 0.81 | SMN1; SMN2 (0.44) | LMNATSHRSMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL2929927 | 0.80 | HSD17B2 (0.40) | LMNATSHRSMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL27358960 | 0.80 | TSHR (0.46) | TSHRSMN1; SMN2CYP3A4ALDH1A1ALOX15 | |
| SCHEMBL23145144 | 0.79 | CYP3A4 (0.42) | LMNATSHRSMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL3398998 | 0.79 | MEN1 (0.50) | LMNATSHRSMN1; SMN2TDP1GAA | |
| SCHEMBL8522276 | 0.79 | LMNA (0.51) | LMNATSHRCYP3A4ALDH1A1ALOX15 | |
| SCHEMBL22112765 | 0.79 | LMNA (0.51) | LMNATSHRSMN1; SMN2CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6268852 | 0.79 | HSD17B2 (0.40) | LMNATSHRSMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL17761960 | 0.78 | LMNA (0.56) | LMNAALDH1A1KDM4EHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2025-07-29 | — | — | US | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| CN-110214141-B | Benzodiazolium compounds as ENaC inhibitors | 企业治疗学有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20210188855-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-06-24 | — | — | US | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20190233402-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2019-08-01 | — | — | US | disclosed |
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | LMNA 2444/4885TSHR 1771/4885SMN1; SMN2 3415/4885 |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | LMNA 2444/4885TSHR 1771/4885SMN1; SMN2 3415/4885 |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | SCNN1B, SCNN1A, SCNN1G | LMNA 1457/4885TSHR 1035/4885SMN1; SMN2 2400/4885 |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | LMNA 4351/4885TSHR 261/4885SMN1; SMN2 1550/4885 |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | LMNA 2568/4885TSHR 1697/4885SMN1; SMN2 3788/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | LMNA 3250/4885TSHR 1688/4885SMN1; SMN2 4524/4885 |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | LMNA 3985/4885TSHR 4379/4885SMN1; SMN2 1976/4885 |
| US-20190233402-A1 | COMPOUNDS | CFTR, NHERF1, SCNN1A | LMNA 1281/4885TSHR 1427/4885SMN1; SMN2 3115/4885 |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | LMNA 2568/4885TSHR 1697/4885SMN1; SMN2 3788/4885 |
| US-20210188855-A1 | COMPOUNDS | NHERF1, SCNN1B, SCNN1A | LMNA 1964/4885TSHR 906/4885SMN1; SMN2 2572/4885 |
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | LMNA 2568/4885TSHR 1697/4885SMN1; SMN2 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.